CVSA
Covista Inc.
CVSA has the edge over RIVN overall, supported by lower modeled downside and stronger valuation.
RIVN
Rivian Automotive, Inc.
RIVN's outlook is improving, though it still trails on the overall score.
CVSA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
CVSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
RIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
RIVN's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CVSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $44.17 | -63% |
| Forward | 13x | $119 | — |
| Current | 16x | $119 | — |
| Fair | 18x | $135 | +14% |
| Expensive | 24x | $173 | +46% |
Historical ranges are pointers, not guarantees.
CVSA's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
RIVN PE Valuation
RIVN has no meaningful PE right now: it lost money over the past year.
CVSA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CVSA, with profitability improving.
RIVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RIVN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CVSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.18 | +25% |
| Q3 2026 | $7.32 | +9.7% |
| Q2 2026 | $7.04 | +14% |
| Q1 2026 | $6.41 | +7.2% |
| Q4 2025 | $6.80 | +28% |
| Q3 2025 | $6.67 | +54% |
| Q2 2025 | $6.18 | +82% |
| Q1 2025 | $5.98 | +127% |
| Q4 2024 | $5.32 | +96% |
CVSA has the edge over RIVN on earnings quality, reporting a profit while its opponent remains loss making.
RIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.25 | +$0.83 |
| Q2 2026 | -$2.58 | +$0.62 |
| Q1 2026 | -$2.92 | +$0.77 |
| Q4 2025 | -$3.07 | +$1.62 |
| Q3 2025 | -$3.08 | +$2.52 |
| Q2 2025 | -$3.20 | +$2.76 |
| Q1 2025 | -$3.69 | +$2.08 |
| Q4 2024 | -$4.69 | +$1.05 |
RIVN is still losing money, but far less than before: $2.25 per share over the past year, against $7.40 at its worst in late 2022.
CVSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $511.5M | +11% |
| Q2 2026 | $501.4M | +9.7% |
| Q1 2026 | $487M | +4.5% |
| Q4 2025 | $503.4M | +12% |
| Q3 2025 | $462.3M | +11% |
| Q2 2025 | $457.1M | +12% |
| Q1 2025 | $466.1M | +13% |
| Q4 2024 | $447.7M | +14% |
CVSA's revenue has grown year over year for 15 quarters in a row: $512M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.7 points |
| Q2 2026 | 19% | +2.2 points |
| Q1 2026 | 19% | -0.7 points |
| Q4 2025 | 22% | -1.1 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 17% | +0.1 points |
| Q1 2025 | 19% | +4.5 points |
| Q4 2024 | 23% | +8.3 points |
CVSA has the edge over RIVN on profitability, with a higher operating margin.
RIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2B | +38% |
| Q2 2026 | $1.7B | +27% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.3B | -26% |
| Q3 2025 | $1.6B | +78% |
| Q2 2025 | $1.3B | +13% |
| Q1 2025 | $1.2B | +3% |
| Q4 2024 | $1.7B | +32% |
RIVN's revenue is growing: $2.2B last quarter, up 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -41% | +22 points |
| Q2 2026 | -50% | +35 points |
| Q1 2026 | -64% | -11 points |
| Q4 2025 | -65% | -27 points |
| Q3 2025 | -63% | +71 points |
| Q2 2025 | -86% | +33 points |
| Q1 2025 | -53% | +70 points |
| Q4 2024 | -38% | +82 points |
RIVN's operating margin was −41% last quarter, up 22 points from the same quarter a year ago, near the top of its range since 2021.
CVSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $76.4M | -33% |
| Q2 2026 | $97.1M | +139% |
| Q1 2026 | $165.9M | -16% |
| Q4 2025 | $15.1M | +$44.8M |
| Q3 2025 | $114.5M | +45% |
| Q2 2025 | $40.7M | -6.8% |
| Q1 2025 | $197.7M | +40% |
| Q4 2024 | -$29.7M | -$7.3M |
CVSA has the edge over RIVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
RIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1B | -$703M |
| Q2 2026 | -$849M | -$451M |
| Q1 2026 | -$1.1B | -$549M |
| Q4 2025 | -$1.1B | -234% |
| Q3 2025 | -$421M | +$732M |
| Q2 2025 | -$398M | +$639M |
| Q1 2025 | -$526M | +$997M |
| Q4 2024 | $856M | +$2.3B |
RIVN has burned cash in almost every quarter: −$4.2B over the past year, against −$489M the year before.
CVSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -1.1M shares |
| 1 year | -6.7% | -2.5M shares |
| 3 years | -18% | -7.6M shares |
| 5 years | -30% | -15.1M shares |
| Available history | -36% | -19.5M shares |
CVSA has the edge over RIVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $81M |
| Q2 2026 | — |
| Q1 2026 | $67.5M |
| Q4 2025 | $164.8M |
| Q3 2025 | $7.6M |
| Q2 2025 | $66.7M |
| Q1 2025 | $72.4M |
| Q4 2024 | $40.9M |
CVSA spent $313M buying back its own shares over the past year, up 67% from the year before.
RIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +121M shares |
| 1 year | +19% | +226M shares |
| 3 years | +52% | +494M shares |
RIVN has 1.4B diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $6M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CVSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 1.2x | Healthy |
CVSA's net debt is less than a year of its operating earnings (EBITDA).
RIVN Net Leverage
RIVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CVSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.3 | Neutral |
| Stochastic | 24.4 | Neutral |
CVSA's weekly RSI is 47 (neutral) and its Stochastic is 24 (neutral).
RIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 25.6 | Neutral |
RIVN's weekly RSI is 41 (neutral) and its Stochastic is 26 (neutral).
CVSA PE vs Consumer Cyclical Sector
| Metric | CVSA | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 9.8% below |
| PE % | 33 | 47 | 14 pts below |
CVSA is trading at 16x earnings, in line with the Consumer Cyclical sector's median of 18x.
RIVN PE vs Consumer Cyclical Sector
RIVN has no meaningful PE right now: it lost money over the past year.
CVSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $123.5 | 3.6% below |
| 20 week MA | $126.4 | 5.8% below |
| 50 week MA | $117.5 | 1.3% above |
| 100 week MA | $116.5 | 2.2% above |
| 200 week MA | $85.9 | 39% above |
CVSA has the edge over RIVN on trend strength, trading above more of its moving averages.
RIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.3 | 3.9% below |
| 20 week MA | $15.1 | 15% below |
| 50 week MA | $15.9 | 19% below |
| 100 week MA | $14.7 | 13% below |
| 200 week MA | $15.1 | 15% below |
RIVN is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
CVSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.0 | $34.4 | -1.8% |
| 2021 | $34.4 | $30.0 | -13% |
| 2022 | $30.0 | $36.2 | +20% |
| 2023 | $36.2 | $59.0 | +63% |
| 2024 | $59.0 | $90.9 | +54% |
| 2025 | $90.9 | $104.7 | +15% |
| 2026 YTD | $104.7 | $119.0 | +14% |
CVSA has the edge over RIVN on returns for 2026, with the stronger performance.
RIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $130.0 | $96.8 | -25% |
| 2022 | $96.8 | $19.1 | -80% |
| 2023 | $19.1 | $23.5 | +23% |
| 2024 | $23.5 | $13.7 | -42% |
| 2025 | $13.7 | $20.9 | +53% |
| 2026 YTD | $20.9 | $12.8 | -39% |
RIVN has finished lower in three of the last five years. It's down 39% so far in 2026.